keyword
https://read.qxmd.com/read/38646491/clinical-significance-of-the-cxcl8-cxcr1-r2-signalling-axis-in-patients-with-invasive-breast-cancer
#21
JOURNAL ARTICLE
Sebastian Stępień, Marta Smycz-Kubańska, Celina Kruszniewska-Rajs, Joanna Magdalena Gola, Jacek Kabut, Paweł Olczyk, Aleksandra Mielczarek-Palacz
The C-X-C motif chemokine ligand 8 (CXCL8)-C-X-C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to assess the expression of these parameters at the mRNA level, considering molecular subtypes and degrees of cancer malignancy...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646441/profiling-of-serum-metabolome-of-breast-cancer-multi-cancer-features-discriminate-between-healthy-women-and-patients-with-breast-cancer
#22
JOURNAL ARTICLE
Katarzyna Mrowiec, Julia Debik, Karol Jelonek, Agata Kurczyk, Lucyna Ponge, Agata Wilk, Marcela Krzempek, Guro F Giskeødegård, Tone F Bathen, Piotr Widłak
INTRODUCTION: The progression of solid cancers is manifested at the systemic level as molecular changes in the metabolome of body fluids, an emerging source of cancer biomarkers. METHODS: We analyzed quantitatively the serum metabolite profile using high-resolution mass spectrometry. Metabolic profiles were compared between breast cancer patients (n=112) and two groups of healthy women (from Poland and Norway; n=95 and n=112, respectively) with similar age distributions...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646434/case-report-unusual-breast-cancer-metastasis-manifesting-as-a-scalp-lesion-in-a-patient-with-invasive-lobular-carcinoma
#23
Nam Hee Koh, Ha Yeun Oh
Breast cancer is the most prevalent cancer in women globally, often leading to distant metastasis in the lung, liver, or bones. Cutaneous metastasis represents an uncommon pattern in breast cancer, but when observed, it tends to manifest in the thorax and upper abdomen, primarily due to lymph node involvement. Therefore, occurrences of cutaneous metastasis on the scalp and extremities are infrequent. Moreover, invasive lobular carcinoma metastasizing to remote skin is rare among the breast cancer. This report presents a case of cutaneous metastasis of invasive lobular carcinoma to the scalp in a patient treated for breast cancer six years ago, with no signs of local recurrence or metastasis to other organs...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646426/targeting-estrogen-mediated-cyp4f2-cyp4f11-20-hete-metabolic-disorder-decelerates-tumorigenesis-in-er-breast-cancer
#24
JOURNAL ARTICLE
Juan Yang, Yin Li, Xiao Han, Tianjiao Li, Ding Li, Qiao Liu, Lizhong Yan, Fei Li, Xiaolin Pei, Ya Feng, Zhoujun Lin, Zhenkun Fu, Changjun Wang, Qiang Sun, Chenggang Li
PURPOSE: As the most common subset of breast cancer (BC), estrogen receptor positive (ER+) BC accounting for 80% of cases, has become a global public health concern. The female hormone estrogen (E2) unequivocally drives ER + breast malignancies. The reasons that estrogen affects BC development has long been considered, yet further study remains to be conducted of the molecular events in the E2-estrogen receptor α (ERα) signaling pathway in ER + BC progression, especially lipid metabolism, so providing more options for tailored and individualized therapy...
July 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38646373/a-rare-and-intriguing-case-report-of-metaplastic-breast-carcinoma
#25
Vallal Kani, Vimal Chander, Sulochana Sonti, Sridevi Manian, Sudha Vasudevan, Muthuvel Esakki, Sarah Grace Priyadarshini, Karthika Rajendran
Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of breast cancer characterized by the presence of both epithelial and mesenchymal components within the tumor. Its clinical and radiological appearance is comparable to other types of breast cancer, but it grows rapidly. The diagnosis of metaplastic carcinoma is largely based on the epithelial origin of the cells confirmed by immunohistochemistry (IHC). Compared to invasive ductal carcinoma, metaplastic carcinoma has a worse overall survival rate...
March 2024: Curēus
https://read.qxmd.com/read/38646367/mucinous-carcinoma-of-the-breast-a-case-report
#26
Jayashree Rey, Samarth Shukla, Sourya Acharya, Pravin Gadkari, Sapna Sihag
This case report presents the diagnostic journey of a 65-year-old female presenting with symptoms suggestive of breast pathology, ultimately diagnosed with mucinous carcinoma, following comprehensive clinical evaluation and histopathological confirmation. Initial assessments indicated a fibroadenoma; however, subsequent histopathological examination revealed mucinous carcinoma, highlighting the importance of histopathological confirmation in establishing definitive diagnoses. The case underscores the challenges in distinguishing between benign and malignant breast lesions based on clinical presentation and imaging findings alone...
March 2024: Curēus
https://read.qxmd.com/read/38646326/computational-analysis-of-single-nucleotide-polymorphisms-in-human-hic1-gene
#27
JOURNAL ARTICLE
Arora Annanya, Boopathi Priyadharshini, Vasugi Suresh, Elangovan Dilipan
Background A putative tumor suppressor gene called HIC1 (hypermethylated in cancer) is situated at 17p13.3, a locus where the allelic loss occurs often in human malignancies, including breast cancer. Hypermethylated in cancer 1 protein is a protein that in humans is encoded by the HIC1 gene and it's a  Homo sapiens  (Human). This gene functions as a growth regulatory and tumor repressor gene. The molecular function of HIC1 gene includes DNA-binding transcription factor activity, sequence-specific DNA binding, DNA binding, histone deacetylase binding, protein binding, metal ion binding, nucleic acid binding, DNA-binding transcription repressor activity, RNA polymerase II-specific, DNA-binding transcription factor activity, RNA polymerase II-specific...
March 2024: Curēus
https://read.qxmd.com/read/38646223/post-mastectomy-pain-syndrome-a-review-article-and-emerging-treatment-modalities
#28
REVIEW
Jay D Shah, Kennedy Kirkpatrick, Krishna Shah
Post-mastectomy pain syndrome (PMPS) is a syndrome broadly applied to the development of chronic pain after surgical breast intervention (i.e., lumpectomy and mastectomy). The incidence of PMPS is likely underreported, and this has contributed to a paucity of high-level evidence related to the treatment of the aforementioned condition. A drive to reduce the burden of opioid use has led to pain management physicians trialing a variety of strategies to help patients manage PMPS. This review discusses the latest evidence behind treatment options for PMPS, exploring medications as well as interventional techniques (e...
March 2024: Curēus
https://read.qxmd.com/read/38645759/treatment-options-for-early-stage-inoperable-breast-cancer-cryoablation-or-radiotherapy
#29
REVIEW
Gail Wan Ying Chua, Lucia Li
BACKGROUND: Surgical removal of the tumour is the gold standard treatment for early stage invasive breast cancer. However, with a global ageing population, a larger number of diagnoses are occurring in women with comorbidities that render them unsuitable for surgery. Hence, it is of interest to explore alternative treatment strategies for this group of women. SUMMARY: Our narrative review aims to explore two such techniques, cryoablation and external beam radiotherapy, providing a brief summary of the evidence behind each technique...
April 2024: Breast Care
https://read.qxmd.com/read/38645685/impact-of-systemic-therapy-on-fertility-in-women-with-early-stage-breast-cancer
#30
JOURNAL ARTICLE
Kelsey H Natsuhara, A Jo Chien
PURPOSE OF REVIEW: Fertility concerns are common among young women diagnosed with breast cancer, as systemic therapy increases the risk of premature ovarian insufficiency and delays family planning. Here, we review the impact of systemic therapies, including chemotherapy, endocrine therapy, HER-2 directed therapy, PARP inhibitors, and immunotherapy, on ovarian reserve. RECENT FINDINGS: With an improved understanding of disease biology, fewer women are treated with gonadotoxic chemotherapy...
March 2024: Current Breast Cancer Reports
https://read.qxmd.com/read/38645612/the-application-of-tdcs-to-treat-pain-and-psychocognitive-symptoms-in-cancer-patients-a-scoping-review
#31
REVIEW
Benedetta Capetti, Lorenzo Conti, Chiara Marzorati, Roberto Grasso, Roberta Ferrucci, Gabriella Pravettoni
BACKGROUND: The use of transcranial direct current stimulation (tDCS) to modulate pain, psychological aspects, and cognitive functions has increased in recent years. The present scoping review aims to investigate the use of tDCS in cancer patients and its significant impact on psychocognitive and pain related symptoms. METHODS: From the earliest available date to June 2023, a comprehensive search was conducted in three electronic scientific databases-PubMed, Scopus, and Embase-and other supplementary sources...
2024: Neural Plasticity
https://read.qxmd.com/read/38645566/retraction-case-report-a-rare-case-of-tumor-to-tumor-metastasis-metastatic-lobular-breast-carcinoma-to-clear-cell-renal-cell-carcinoma
#32
(no author information available yet)
[This retracts the article DOI: 10.3389/pore.2023.1611204.].
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38645515/construction-of-glutathione-responsive-paclitaxel-prodrug-nanoparticles-for-image-guided-targeted-delivery-and-breast-cancer-therapy
#33
JOURNAL ARTICLE
Weiwei Ma, Qiufeng Zhao, Shilong Zhu, Xinyue Wang, Chuangchuang Zhang, Daming Ma, Na Li, Yanyan Yin
Paclitaxel (PTX) remains an essential drug in the treatment of breast cancer. To improve metabolic stability and real-time monitoring of drug location, we develop a visualized nano-prodrug. Novel hyaluronic acid (HA)-coated glutathione (GSH)-sensitive chitosan (CS)-based nano-prodrug (HA/TPE-CS-SS-PTX NPs) with aggregation-induced emission effects (AIE) were accomplished. The prodrug NPs (drug loading 29.32%, particle size 105 nm, regular sphericity) exhibit excellent fluorescence stability. The prodrug NPs could target tumor cells with high expression of CD44 and decompose in the presence of high concentrations of glutathione...
April 16, 2024: RSC Advances
https://read.qxmd.com/read/38645502/underlying-anti-cancer-mechanisms-of-histone-deacetylase-hdac-inhibitors-in-tamoxifen-resistant-breast-cancer-cells
#34
JOURNAL ARTICLE
Lingyan Wang, Yukai Xu, Chunhui Gao
OBJECTIVES: Breast cancer is an important women's malignancy with high cancer-related deaths worldwide. Drug resistance lowers the treatment efficacy in this malignancy. This study aimed to explore the underlying mechanisms of histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to overcome resistance to tamoxifen in breast cancer cells. MATERIALS AND METHODS: Tamoxifen-resistance in MCF-7 breast cancer cells was simulated. MTT assay was used to detect the cytotoxic effects of HDAC inhibitor and PI3K inhibitor on the cancer cells...
2024: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/38645485/tmbcalc-a-computational-pipeline-for-identifying-pan-cancer-tumor-mutational-burden-gene-signatures
#35
JOURNAL ARTICLE
Grete Francesca Privitera, Salvatore Alaimo, Anna Caruso, Alfredo Ferro, Stefano Forte, Alfredo Pulvirenti
BACKGROUND: In the precision medicine era, identifying predictive factors to select patients most likely to benefit from treatment with immunological agents is a crucial and open challenge in oncology. METHODS: This paper presents a pan-cancer analysis of Tumor Mutational Burden (TMB). We developed a novel computational pipeline, TMBcalc, to calculate the TMB. Our methodology can identify small and reliable gene signatures to estimate TMB from custom targeted-sequencing panels...
2024: Frontiers in Genetics
https://read.qxmd.com/read/38645412/link-a-unveiling-its-functional-role-and-clinical-significance-in-human-tumors
#36
REVIEW
Bing Liao, Jialing Wang, Yilin Xie, Hongliang Luo, Jun Min
LINK-A, also recognized as LINC01139, has emerged as a key oncological lncRNA in cancer. LINK-A is upregulated in solid and liquid tumor samples, including breast cancer, ovarian cancer, glioma, non-small-cell lung cancer, and mantle cell lymphoma. Notably, LINK-A is involved in regulating critical cancer-related pathways, such as AKT and HIF1α signaling, and is implicated in a range of oncogenic activities, including cell proliferation, apoptosis, epithelial-mesenchymal transition (EMT), cell invasion and migration, and glycolysis reprogramming...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38645356/brca-mutations-and-microrna-expression-patterns-in-the-peripheral-blood-of-breast-cancer-patients
#37
JOURNAL ARTICLE
Ceren Alavanda, Esra Dirimtekin, Maria Mortoglou, Esra Arslan Ates, Ahmet Ilter Guney, Pinar Uysal-Onganer
Breast cancer (BC) persists as the predominant malignancy globally, standing as the foremost cause of cancer-related mortality among women. Despite notable advancements in prevention and treatment, encompassing the incorporation of targeted immunotherapies, a continued imperative exists for the development of innovative methodologies. These methodologies would facilitate the identification of women at heightened risk, enhance the optimization of therapeutic approaches, and enable the vigilant monitoring of emergent treatment resistance...
April 16, 2024: ACS Omega
https://read.qxmd.com/read/38645250/expression-of-c-erb-b2-oncoprotein-as-a-neoantigen-strategy-to-repurpose-anti-neu-antibody-therapy-in-a-model-of-melanoma
#38
Emmanuel M Gabriel, Brian Necela, Deborah Bahr, Sneha Vivekanandhan, Barath Shreeder, Sanjay Bagaria, Keith L Knutson
In this study, we tested a novel approach of "repurposing" a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2 (the animal homolog to HER2/neu). This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7...
April 3, 2024: Research Square
https://read.qxmd.com/read/38645169/respiratory-viral-infection-promotes-the-awakening-and-outgrowth-of-dormant-metastatic-breast-cancer-cells-in-lungs
#39
Shi B Chia, Bryan J Johnson, Junxiao Hu, Roel Vermeulen, Marc Chadeau-Hyam, Fernando Guntoro, Hugh Montgomery, Meher Preethi Boorgula, Varsha Sreeka, Andrew Goodspeed, Bennett Davenport, Felipe V Pereira, Vadym Zaberezhnyy, Wolfgang E Schleicher, Dexiang Gao, Andreia N Cadar, Michael Papanicolaou, Afshin Beheshti, Stephen B Baylin, James Costello, Jenna M Bartley, Thomas E Morrison, Julio A Aguirre-Ghiso, Mercedes Rincon, James DeGregori
Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy 1 . Understanding the mechanisms that disrupt the quiescence of dormant disseminated cancer cells (DCC) is crucial for addressing metastatic progression. Infection with respiratory viruses (e.g. influenza or SARS-CoV-2) is common and triggers an inflammatory response locally and systemically 2,3 . Here we show that influenza virus infection leads to loss of the pro-dormancy mesenchymal phenotype in breast DCC in the lung, causing DCC proliferation within days of infection, and a greater than 100-fold expansion of carcinoma cells into metastatic lesions within two weeks...
April 5, 2024: Research Square
https://read.qxmd.com/read/38645153/role-of-numa1-in%C3%A2-breast-cancer-stem-cells-with-implications-for-combination-therapy-of-pim1-and-autophagy-inhibition-in-triple-negative-breast-cancer
#40
Kanakaraju Manupati, Mingang Hao, Michael Haas, Syn Kok Yeo, Jun-Lin Guan
BACKGROUND: Nuclear mitotic apparatus protein 1 (NuMA1) is a cell cycle protein and upregulated in breast cancer. However, the role of NuMA1 in TNBC and its regulation in heterogenous populations remains elusive. METHODS: We performed CRISPR mediated deletion of NuMA1 in mouse TNBC cells, BF3M. FACS was utilized to isolate BCSCs, and bulk cells based on CD29 and CD61 markers. Cell viability, migration, and invasion ability of BCSCs and bulk cells was evaluated using MTT, wound healing and transwell invasion assays, respectively...
April 1, 2024: Research Square
keyword
keyword
55032
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.